ArticleBMC cancer2025
Prevalence and clinical significance of the rare HOXB13 X285K variant in a French Caribbean prostate cancer cohort.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe HOXB13 gene has been associated with hereditary prostate cancer (PCa), with rare germline variants linked to early-onset and aggressive forms of the disease. While the G84E variant has been well-characterized in Caucasian populations, the clinical relevance of the X285K variant-primarily found in individuals of African ancestry-remains unclear. This study aimed to determine the prevalence of HOXB13 X285K in a French Caribbean cohort and explore its association with adverse clinical features.
methodsWe conducted a prospective cohort study including 465 men diagnosed with prostate cancer. Germline sequencing of HOXB13 was performed using Sanger methodology to identify the presence of the X285K variant.
resultsThe HOXB13 X285K variant was identified in 5 patients (1.07%). All carriers had clinically significant disease. Among them, three presented with de novo metastatic prostate cancer, and two with intermediate-risk localized disease experienced early biochemical recurrence (at 22 and 34 months). In contrast, recurrence-free survival exceeded 85% at 50 months in the overall cohort.
conclusionsAlthough limited by small sample size, these findings suggest a possible link between the HOXB13 X285K variant and early tumor progression. This highlights the importance of screening for this rare variant, particularly in patients of African descent who are underrepresented in genomic studies, to support improved risk stratification and personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.